Your browser doesn't support javascript.
Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications.
Caronna, E; José Gallardo, V; Alpuente, A; Torres-Ferrus, M; Sánchez-Mateo, N M; Viguera-Romero, J; López-Veloso, A C; López-Bravo, A; Gago-Veiga, A B; Irimia Sieira, P; Porta-Etessam, J; Santos-Lasaosa, S; Pozo-Rosich, P.
  • Caronna E; Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona
  • José Gallardo V; Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Alpuente A; Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona
  • Torres-Ferrus M; Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona
  • Sánchez-Mateo NM; Headache Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Viguera-Romero J; Headache Unit, Neuroscience Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • López-Veloso AC; Neurology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain.
  • López-Bravo A; Neurology Department, Hospital Reina Sofia, Tudela, Spain.
  • Gago-Veiga AB; Headache Unit, Neurology Department, Hospital Universitario de La Princesa & Instituto de Investigación Sanitaria de La Princesa, Madrid, Spain.
  • Irimia Sieira P; Neurology Department, Clinica Universidad de Navarra, Pamplona, Spain.
  • Porta-Etessam J; Department of Neurology, Institute of Neurosciences, Hospital Clínico San Carlos, IdISSC, Universidad Complutense de Madrid, Madrid, Spain.
  • Santos-Lasaosa S; Headache Unit, Neurology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
  • Pozo-Rosich P; Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona
Neurologia (Engl Ed) ; 36(8): 611-617, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1469897
ABSTRACT
BACKGROUND AND

OBJECTIVE:

CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus.

METHODS:

This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms.

RESULTS:

We recruited 300 patients with migraine 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P=.320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment.

CONCLUSION:

Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Migraine Disorders Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Female / Humans / Middle aged Language: English Journal: Neurologia (Engl Ed) Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Migraine Disorders Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Female / Humans / Middle aged Language: English Journal: Neurologia (Engl Ed) Year: 2021 Document Type: Article